Pharmacological treatment for COVID-19 included antivirals (45.6%), azithromycin (40.5%), hydroxychloroquine or similar drugs (37.9%), anti-IL6 or anti-IL6R monoclonal antibodies (19.1%), and convalescent hyperimmune plasma (10.1%). The gene discussed is IL6R; the disease is COVID-19.